ABDX Stock Overview
Abingdon Health Plc engages in the development, manufacture, and distribution of diagnostic devices in the United Kingdom, the United States, Canada, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Abingdon Health Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.098 |
| 52 Week High | UK£0.18 |
| 52 Week Low | UK£0.065 |
| Beta | 0.13 |
| 1 Month Change | -2.50% |
| 3 Month Change | 6.56% |
| 1 Year Change | 2.63% |
| 3 Year Change | -82.43% |
| 5 Year Change | n/a |
| Change since IPO | -90.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABDX | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | -2.5% | 1.3% | 1.0% |
| 1Y | 2.6% | -9.2% | 3.0% |
Return vs Industry: ABDX exceeded the UK Medical Equipment industry which returned -11.4% over the past year.
Return vs Market: ABDX matched the UK Market which returned 3.5% over the past year.
Price Volatility
| ABDX volatility | |
|---|---|
| ABDX Average Weekly Movement | 11.1% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: ABDX's share price has been volatile over the past 3 months.
Volatility Over Time: ABDX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 84 | Chris Henry Yates | www.abingdonhealth.com |
Abingdon Health Plc engages in the development, manufacture, and distribution of diagnostic devices in the United Kingdom, the United States, Canada, Europe, and internationally. The company provides Abingdon Simply Test, a range of self-tests in the field of fertility, health and well-being, infectious diseases, and drug testing; PCRD and PCRD FLEX, are nucleic acid lateral flow tests, which are used for rapid readouts post isothermal amplification; and 2019-nCoV Antigen Test, a rapid lateral flow test for the qualitative detection of antigens to SARS-CoV-2, as well as plant health tests; and nucleic acid lateral flow immunoassays. It also offers AppDx, a customizable image capturing technology that transforms a smartphone into a self-sufficient and standalone lateral-flow reader; and Salistick, a rapid saliva-based pregnancy test.
Abingdon Health Plc Fundamentals Summary
| ABDX fundamental statistics | |
|---|---|
| Market cap | UK£30.03m |
| Earnings (TTM) | -UK£2.23m |
| Revenue (TTM) | UK£5.34m |
5.6x
P/S Ratio-13.4x
P/E RatioIs ABDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABDX income statement (TTM) | |
|---|---|
| Revenue | UK£5.34m |
| Cost of Revenue | UK£2.28m |
| Gross Profit | UK£3.07m |
| Other Expenses | UK£5.30m |
| Earnings | -UK£2.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0073 |
| Gross Margin | 57.35% |
| Net Profit Margin | -41.82% |
| Debt/Equity Ratio | 39.7% |
How did ABDX perform over the long term?
See historical performance and comparison